Achillion's CEO Milind Desh­pande steps down; Neu­ro­Vi­sion rais­es $11.2M for nov­el Alzheimer's de­tec­tion tech

Milind Desh­pande

Milind Desh­pande is step­ping down from Achillion $ACHN, the biotech he’s led for the bet­ter part of the last two decades, first as CSO and then as CEO. His de­par­ture leaves the fad­ed hep C star in the hands of for­mer COO Joseph Tru­itt, who al­ready has the pres­i­dent ti­tle. Dur­ing his tenure, Desh­pande steered a pipeline re­struc­tur­ing that re­brand­ed Achillion from an in­fec­tious dis­ease play­er to a spe­cial­ist in com­ple­ment bi­ol­o­gy, ax­ing staff just a few months ago. Tru­itt, who joined the com­pa­ny in 2009, emerged as a key fig­ure in that come­back nar­ra­tive. Hav­ing led com­mer­cial strat­e­gy and busi­ness de­vel­op­ment, he will now prep Achillion for a se­ries of read­outs from its com­ple­ment fac­tor D in­hibitor pro­gram in rare dis­eases.

Neu­ro­Vi­sion, a com­pa­ny de­vel­op­ing a non-in­va­sive di­ag­nos­tic for Alzheimer’s dis­ease, has raised $11.2 mil­lion out of $15 mil­lion in planned Se­ries C fi­nanc­ing. Sacra­men­to, CA-based Neu­ro­Vi­sion at­tract­ed the back­ing of Wild­cat Cap­i­tal Man­age­ment, J&J In­no­va­tion and oth­er in­vestors with an eye imag­ing sys­tem that aims to de­tect amy­loid be­ta plaque via the reti­na. Giv­en that amy­loid be­ta plaque de­posits in the brain are a hall­mark of Alzheimer’s dis­ease but are in­con­ve­nient and ex­pen­sive to de­tect, ex­ecs say, this new tech­nol­o­gy of­fers a low-cost al­ter­na­tive that could lead to ear­li­er de­tec­tion of dis­ease as well as eas­i­er screen­ing in clin­i­cal tri­als. Neu­ro­vi­sion is on track to seek reg­u­la­to­ry ap­proval for the tech, which was li­censed from Cedars-Sinai Med­ical Cen­ter in Los An­ge­les.

→ UK gene edit­ing com­pa­ny Hori­zon Dis­cov­ery has snubbed a $370 mil­lion takeover bid by Ab­cam, an in­ter­na­tion­al re­search tool com­pa­ny. The pro­pos­al was re­ject­ed de­spite the fact that Ab­cam of­fered a price that rep­re­sent­ed a 26% pre­mi­um to Hori­zon’s clos­ing price on May 1. Ab­cam, which makes an­ti­bod­ies, pro­teins, and oth­er prod­ucts for re­searchers, is build­ing a new glob­al head­quar­ters at Cam­bridge Bio­med­ical Cam­pus and is on the hunt for strate­gic takeovers. Hori­zon would make a pret­ty match, Ab­cam says, al­low­ing each com­pa­ny to ex­pand their reach glob­al­ly. Ab­cam is pitch­ing that idea to Hori­zon’s share­hold­ers by go­ing pub­lic with its bid pro­pos­al. Shares in Hori­zon jumped 36% on the Lon­don ex­change on the news.

With con­tri­bu­tion by Brit­tany Meil­ing

Com­mu­ni­cat­ing the val­ue of pre­ci­sion med­i­cine

By Natasha Cowan, Content Marketing Manager at Blue Latitude Health.
Many stakeholders are confused by novel precision medicines, including patients and healthcare professionals. So, how can industry help them to navigate this complexity?

Precision medicine represents a new paradigm in healthcare. It embodies the shift from treating many patients with the same therapy, to having the tools to identify the best treatment for every patient.

FDA pan­el large­ly op­pos­es ex­pand­ing use of Lil­ly, Boehringer's SGLT2 in­hibitor to type I di­a­bet­ics

Last week, Eli Lilly and partner Boehringer Ingelheim rejigged the terms of their 2011 diabetes pact that nurtured the development of their blockbuster Jardiance franchise. Akin to manufacturers of rival SGLT2 drugs, the companies are working to expanding the use of their type II diabetes drug to reach a broader group of patients. On Wednesday, an expert panel to the FDA resisted that effort by largely voting against their quest to market the drug in type I diabetics.

Amir Nashat, World Medical Innovation Forum via Youtube

Bay­er bets up to $100M on ex­plor­ing new bio­mol­e­c­u­lar con­den­sate ter­rain with a biotech up­start

In the Indiana Jones warehouse of genomic oddities, the millions of units of so-called “junk DNA” that create nothing but play a hand in tons of things have grabbed most of the attention. But there are other arks and Templar crosses out there.

Among them: the code for intrinsically disordered regions. Floating like boundless clumps of boiling spaghetti throughout the cell, these regions first appeared in scientific sketches at the turn of the century before vanishing from most cell diagrams, such as those in a high school textbook. Most organelles were neatly bound in membranes. These loose molecules resisted characterization. Scientists largely ignored them.

In­vestors could emerge from Neil Wood­ford de­ba­cle with £1B loss, in­ter­nal analy­sis re­veals

When Link Fund Solutions announced that it is closing Woodford Equity Income Fund permanently and kicking out Neil Woodford, it was implied that investors probably won’t get back everything they entrusted to the fund manager. But nobody knew just how much they would lose.

An internal analysis commissioned by Link suggested that the collective loss could amount to £1 billion — out of a fund last valued at £3.1 billion — Citywire has revealed.

Mer­ck buys a fledg­ling neu­rode­gen­er­a­tive biotech spawned by an old GSK dis­cov­ery al­liance. What’s up with that?

Avalon Ventures chief Jay Lichter has a well-known yen for drug development programs picked up in academia. And what he found in Haoxing Xu’s lab at the University of Michigan pricked his interest enough to launch one of his umbrella biotechs in San Diego.
Xu’s work laid the foundation for Avalon to launch Calporta, which has been working on finding small molecule agonists of TRPML1 (transient receptor potential cation channel, mucolipin subfamily, member 1) for lysosomal storage disorders. And that pathway, they believe, points to new approaches on major market neurodegenerative diseases like Parkinson’s, ALS and Alzheimer’s.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,400+ biopharma pros reading Endpoints daily — and it's free.

GSK's asth­ma bi­o­log­ic Nu­cala scores in rare blood dis­or­der study

GlaxoSmithKline’s asthma drug Nucala, which received a resounding FDA rejection for use in chronic obstructive pulmonary disease (COPD) last year, has shown promise in a rare blood disorder.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,400+ biopharma pros reading Endpoints daily — and it's free.

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women in bio­phar­ma R&D who worked their way to the top

What differentiates a woman leader in biopharma R&D from a man?

Not much, except there are fewer of them in senior posts. Data suggest women are not more risk-averse, family-oriented or less confident than their male counterparts — indeed the differences between the two sexes are negligible. But a glance at the top R&D positions in Big Pharma leaves little doubt that upward migration in the executive ranks of biopharma R&D is tough.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,400+ biopharma pros reading Endpoints daily — and it's free.

FDA Vas­cepa re­view spot­lights new safe­ty sig­nals, pos­si­ble min­er­al oil spoil­er as Amarin hunts a block­buster ap­proval

An in-house FDA review of Amarin’s Vascepa raises a set of hurdles the biotech will have to clear if the biotech expects to get the long-awaited FDA approval that could set it on a path to superstar status. But it appears that Amarin has survived another potential setback without introducing a major new threat to its prospects.

The stakes don’t get much higher, with analysts saying a win this week for Amarin could lead to billions in new sales — provided the agency stamps it with an OK. And investors liked what they say in the FDA review this morning, bumping the stock $AMRN 17%.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,400+ biopharma pros reading Endpoints daily — and it's free.

FDA slaps a hold on an AML tri­al as Mark­er scraps a fail­ing ovar­i­an can­cer pro­gram, sink­ing shares

The FDA has placed a hold on a Phase II AML trial from the small immuno-oncology biotech Marker Therapeutics. Marker disclosed the issue two weeks after responding to FDA concerns, adding it to the Q3 release Tuesday. The company also announced it was scrapping a Phase II ovarian cancer program it determined was unlikely to succeed.

The agency’s concern centers around two reagents used in manufacturing for their trial for acute myeloid leukemia patients who have received a stem cell transplant. The reagents are from third parties and not present in the final product, Marker said.